Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma

• Main Authors: Koen G. A. M. Hussaarts (Author), Leni van Doorn (Author), Sander Bins (Author), Dave Sprengers (Author), Peter de Bruijn (Author), Roelof W. F. van Leeuwen (Author), Stijn L. W. Koolen (Author), Teun van Gelder (Author), Ron H. J. Mathijssen (Author)
• Format: Book
• Published: MDPI AG, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Hepatocellular carcinoma (HCC) recurrence after liver transplantation occurs in approximately 20% of patients. Most of these patients use immunosuppressant drugs. Meanwhile, patients with HCC recurrence are frequently treated with the small molecule kinase inhibitor (SMKI) sorafenib. However, sorafe...